PARP-1 Inhibition as a Targeted Strategy to Treat Ewing's Sarcoma

被引:210
作者
Brenner, J. Chad [1 ,2 ,5 ]
Feng, Felix Y. [1 ,3 ,7 ]
Han, Sumin [3 ]
Patel, Sonam [1 ,2 ]
Goyal, Siddharth V. [1 ,2 ]
Bou-Maroun, Laura M. [1 ,2 ]
Liu, Meilan [3 ]
Lonigro, Robert [1 ,2 ]
Prensner, John R. [1 ,2 ]
Tomlins, Scott A. [1 ,2 ]
Chinnaiyan, Arul M. [1 ,2 ,4 ,5 ,6 ,7 ]
机构
[1] Univ Michigan, Michigan Ctr Translat Pathol, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA
[3] Univ Michigan, Dept Radiat Oncol, Ann Arbor, MI 48109 USA
[4] Univ Michigan, Dept Urol, Ann Arbor, MI 48109 USA
[5] Univ Michigan, Program Cellular & Mol Biol, Ann Arbor, MI 48109 USA
[6] Univ Michigan, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA
[7] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA
关键词
ETS TRANSCRIPTION FACTOR; POLY(ADP-RIBOSE) POLYMERASE; PROSTATE-CANCER; BINDING; FUSION; CHROMATIN; TUMORS; GENES; CELLS;
D O I
10.1158/0008-5472.CAN-11-3648
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Ewing's sarcoma family of tumors (ESFT) refers to aggressive malignancies which frequently harbor characteristic EWS-FLI1 or EWS-ERG genomic fusions. Here, we report that these fusion products interact with the DNA damage response protein and transcriptional coregulator PARP-1. ESFT cells, primary tumor xenografts, and tumor metastases were all highly sensitive to PARP1 inhibition. Addition of a PARP1 inhibitor to the second-line chemotherapeutic agent temozolamide resulted in complete responses of all treated tumors in an EWS-FLI1-driven mouse xenograft model of ESFT. Mechanistic investigations revealed that DNA damage induced by expression of EWS-FLI1 or EWS-ERG fusion genes was potentiated by PARP1 inhibition in ESFT cell lines. Notably, EWS-FLI1 fusion genes acted in a positive feedback loop to maintain the expression of PARP1, which was required for EWS-FLI-mediated transcription, thereby enforcing oncogene-dependent sensitivity to PARP-1 inhibition. Together, our findings offer a strong preclinical rationale to target the EWS-FLI1:PARP1 intersection as a therapeutic strategy to improve the treatment of ESFTs. Cancer Res; 72(7); 1608-13. (C)2012 AACR.
引用
收藏
页码:1608 / 1613
页数:6
相关论文
共 19 条
[1]   Mechanistic Rationale for Inhibition of Poly(ADP-Ribose) Polymerase in ETS Gene Fusion-Positive Prostate Cancer [J].
Brenner, J. Chad ;
Ateeq, Bushra ;
Li, Yong ;
Yocum, Anastasia K. ;
Cao, Qi ;
Asangani, Irfan A. ;
Patel, Sonam ;
Wang, Xiaoju ;
Liang, Hallie ;
Yu, Jindan ;
Palanisamy, Nallasivam ;
Siddiqui, Javed ;
Yan, Wei ;
Cao, Xuhong ;
Mehra, Rohit ;
Sabolch, Aaron ;
Basrur, Venkatesha ;
Lonigro, Robert J. ;
Yang, Jun ;
Tomlins, Scott A. ;
Maher, Christopher A. ;
Elenitoba-Johnson, Kojo S. J. ;
Hussain, Maha ;
Navone, Nora M. ;
Pienta, Kenneth J. ;
Varambally, Sooryanarayana ;
Feng, Felix Y. ;
Chinnaiyan, Arul M. .
CANCER CELL, 2011, 19 (05) :664-678
[2]   Translocations in epithelial cancers [J].
Brenner, J. Chad ;
Chinnaiyan, Arul M. .
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2009, 1796 (02) :201-215
[3]   Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase [J].
Bryant, HE ;
Schultz, N ;
Thomas, HD ;
Parker, KM ;
Flower, D ;
Lopez, E ;
Kyle, S ;
Meuth, M ;
Curtin, NJ ;
Helleday, T .
NATURE, 2005, 434 (7035) :913-917
[4]   Ewing's sarcoma: diagnostic, and therapeutic implications of molecular abnormalities [J].
Burchill, SA .
JOURNAL OF CLINICAL PATHOLOGY, 2003, 56 (02) :96-102
[5]   EWS-FL11 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma [J].
de Alava, E ;
Kawai, A ;
Healey, JH ;
Fligman, I ;
Meyers, PA ;
Huvos, AG ;
Gerald, WL ;
Jhanwar, SC ;
Argani, P ;
Antonescu, CR ;
Pardo-Mindan, FJ ;
Ginsberg, J ;
Womer, R ;
Lawlor, ER ;
Wunder, J ;
Andrulis, I ;
Sorensen, PHB ;
Barr, FG ;
Ladanyi, M .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (04) :1248-1255
[6]   ABT-888, an orallyactive poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models [J].
Donawho, Cherrie K. ;
Luo, Yan ;
Luo, Yanping ;
Penning, Thomas D. ;
Bauch, Joy L. ;
Bouska, Jennifer J. ;
Bontcheva-Diaz, Velitchka D. ;
Cox, Bryan F. ;
DeWeese, Theodore L. ;
Dillehay, Larry E. ;
Ferguson, Debra C. ;
Ghoreishi-Haack, Nayereh S. ;
Grimm, David R. ;
Guan, Ran ;
Han, Edward K. ;
Holley-Shanks, Rhonda R. ;
Hristov, Boris ;
Idler, Kenneth B. ;
Jarvis, Ken ;
Johnson, Eric F. ;
Kleinberg, Lawrence R. ;
Klinghofer, Vered ;
Lasko, Loren M. ;
Liu, Xuesong ;
Marsh, Kennan C. ;
McGonigal, Thomas P. ;
Meulbroek, Jonathan A. ;
Olson, Amanda M. ;
Palma, Joann P. ;
Rodriguez, Luis E. ;
Shi, Yan ;
Stavropoulos, Jason A. ;
Tsurutani, Alan C. ;
Zhu, Gui-Dong ;
Rosenberg, Saul H. ;
Giranda, Vincent L. ;
Frost, David J. .
CLINICAL CANCER RESEARCH, 2007, 13 (09) :2728-2737
[7]   Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy [J].
Farmer, H ;
McCabe, N ;
Lord, CJ ;
Tutt, ANJ ;
Johnson, DA ;
Richardson, TB ;
Santarosa, M ;
Dillon, KJ ;
Hickson, I ;
Knights, C ;
Martin, NMB ;
Jackson, SP ;
Smith, GCM ;
Ashworth, A .
NATURE, 2005, 434 (7035) :917-921
[8]   Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers. [J].
Fong, Peter C. ;
Boss, David S. ;
Yap, Timothy A. ;
Tutt, Andrew ;
Wu, Peijun ;
Mergui-Roelvink, Marja ;
Mortimer, Peter ;
Swaisland, Helen ;
Lau, Alan ;
O'Connor, Mark J. ;
Ashworth, Alan ;
Carmichael, James ;
Kaye, Stan B. ;
Schellens, Jan H. M. ;
de Bono, Johann S. .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (02) :123-134
[9]   NAD+-dependent modulation of chromatin structure and transcription by nucleosome binding properties of PARP-1 [J].
Kim, MY ;
Mauro, S ;
Gévry, N ;
Lis, JT ;
Kraus, WL .
CELL, 2004, 119 (06) :803-814
[10]   Reciprocal binding of PARP-1 and histone H1 at promoters specifies transcriptional outcomes [J].
Krishnakumar, Raga ;
Gamble, Matthew J. ;
Frizzell, Kristine M. ;
Berrocal, Jhoanna G. ;
Kininis, Miltiadis ;
Kraus, W. Lee .
SCIENCE, 2008, 319 (5864) :819-821